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Molecular mechanisms underlying 
AMH elevation in hyperoestrogenic 
states in males
clara Valeri1, María M. Lovaisa1, chrystèle Racine2,3,4, nadia Y. edelsztein1, Marina Riggio5, 
Sebastián Giulianelli5,6, Marcela Venara1, patricia Bedecarrás1, María G. Ballerini1, 
nathalie di clemente2,3, caroline A. Lamb5, Helena f. Schteingart1 & Rodolfo A. Rey 1,7*
Anti-Müllerian hormone (AMH) is secreted by Sertoli cells of the testes from early fetal life until 
puberty, when it is downregulated by androgens. in conditions like complete androgen insensitivity 
syndrome (cAiS), AMH downregulation does not occur and AMH increases at puberty, due in part to 
follicle-stimulating hormone (FSH) effect. However, other conditions like Peutz-Jeghers syndrome 
(PJS), characterised by low FSH, also have increased AMH. Because both CAIS and PJS may present as 
hyperoestrogenic states, we tested the hypothesis that oestradiol (E2) upregulates AMH expression 
in peripubertal Sertoli cells and explored the molecular mechanisms potentially involved. The results 
showed that E2 is capable of inducing an upregulation of endogenous AMH and of the AMH promoter 
activity in the prepubertal Sertoli cell line SMAT1, signalling through ERα binding to a specific ERE 
sequence present on the hAMH promoter. A modest action was also mediated through the membrane 
oestrogen receptor GPER. Additionally, the existence of ERα expression in Sertoli cells in patients 
with CAIS was confirmed by immunohistochemistry. The evidence presented here provides biological 
plausibility to the hypothesis that testicular AMH production increases in clinical conditions in 
response to elevated oestrogen levels.
Anti-Müllerian hormone (AMH), also known as Müllerian inhibitory substance (MIS), is a homodimeric 140-
kDa  glycoprotein1, which belongs to the transforming growth factor β (TGFβ) superfamily. It is encoded by a 
gene of approximately 2.7  kbp2,3 located on human chromosome 19p13.34. The most biologically relevant and 
irreplaceable function of AMH takes place during sex differentiation in early fetal life, when testicular AMH 
secreted by Sertoli  cells5 induces the regression of the paramesonephric Müllerian ducts, which otherwise develop 
to give rise to the Fallopian tubes, the uterus and the upper portion of the  vagina6,7. Although Müllerian duct 
regression is completed early in gestation, Sertoli cells continue to produce AMH until adulthood, and granulosa 
cells of the ovarian follicles also secrete AMH from the second half of  gestation8 until  menopause9,10.
In the fetal Sertoli cell, AMH gene expression is triggered by the nuclear transcription factor  SOX911,12 and 
subsequently upregulated by transcription factors  SF111,13–15,  GATA414,16,17 and  WT118. Thus, high levels of AMH 
are secreted during the period of sex differentiation independently of pituitary gonadotrophin action on Sertoli 
cells. Later, follicle-stimulating hormone (FSH) produced by the pituitary, provokes a surge in AMH testicular 
 output19–21. The molecular pathway induced by the seven-transmembrane domain FSH receptor present on the 
Sertoli cell membrane involves the Gsα  subunit22, cyclic AMP and protein kinase A, which finally activates the 
expression and/or nuclear translocation of transcription factors SOX9, SF1, AP2 and NFκB23–25. During puber-
tal development, testicular AMH production  declines26 as a consequence of the increase of the intratesticular 
concentration of  testosterone19,27 and the emergence of meiotic  spermatocytes19,28. Androgens downregulate 
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AMH expression at the transcriptional level by activating the androgen receptor (AR) which, in turn, blocks 
SF1-induced transactivation of the AMH  promoter29,30.
During the fetal period and early postnatal life, the elevated levels of androgens existing in the testes are 
unable to downregulate AMH expression because Sertoli cells do not express the AR at that  time31–34. Accord-
ingly, AMH levels do not decrease at pubertal age in mice with disrupted androgen  signalling19,35 and in humans 
with defective androgen  synthesis36–38 or with a complete androgen insensitivity syndrome (CAIS) due to AR 
 mutations36–41. In these patients, testes differentiate but virilisation fails; thus, they are born with female external 
genitalia and raised as girls. The diagnosis is made due to the absence of menses at puberty, and in the past, orchi-
ectomy was usually  performed42. Interestingly, at pubertal age testicular AMH  increases36,37 concomitantly with 
FSH and oestradiol levels. FSH can undoubtedly be responsible for the increase in AMH. However, a temporal 
coincidence in the elevation of AMH and oestradiol (E2) also occurs in boys and adolescents with Peutz-Jeghers 
 syndrome43, characterised by the existence of Sertoli cell proliferations overproducing oestrogens that lead to 
low FSH  levels44, and thus cannot explain the increased AMH levels. Interestingly, the human AMH promoter 
contains a consensus sequence for a half-oestrogen response element (ERE)45, and oestradiol has been shown 
to modify AMH expression in the adult  ovary46. Altogether, these observations raise the possibility that the 
hyperoestrogenism observed in CAIS and Peutz-Jeghers syndrome may account for the elevation in testicular 
AMH production.
Oestrogens are steroid hormones synthesised from androgens by aromatase, a member of the cytochrome 
P450 superfamily encoded by only one gene, CYP19A1, in  humans47. During development, aromatase is expressed 
in the human neonatal and infant  testis31, and in the rat testis, aromatisation of androgens to oestrogens is stimu-
lated by the action of FSH on prepubertal Sertoli  cells48. In humans with Klinefelter syndrome, elevated FSH is 
also presumed to increase aromatase activity in Sertoli  cells49, thus resulting in increased oestrogen levels and 
 gynaecomastia50. E2 signals by binding to classical intracellular oestrogen receptors or to a membrane oestrogen 
receptor, known as GPER, GPER1 or  GPR3051. The classical oestrogen receptors α (ERα) and β (ERβ) belong 
to group A of the nuclear receptor subfamily 3, with binding capacity on DNA sequences known as EREs. The 
DNA-binding domains of ERα and ERβ have an identity of 97%, whereas the homology of the ligand-binding 
domains does not exceed 60%; both bind to E2 with a similar  affinity52,53 but differences in this region result in 
variable affinity to diverse synthetic  compounds54. GPER belongs to the family of seven-transmembrane domain, 
G protein-coupled receptors (GPCRs), which classically mediate rapid cellular responses involving kinases, ion 
channels, and second  messengers55. GPER is predominantly localised in the membranes of the endoplasmic 
 reticulum56,57.
Further than synthesising oestrogens, the testes express the different oestrogen receptors, with an ontogeny 
and expressiveness that vary according to the species  studied58. All three ERs have been identified in the different 
human testicular  compartments31,59–61. Although the information on developmental expression of the three ERs 
in the male gonad is scant, in rodent Sertoli cells ERβ seems to be predominant over ERα in the adult, whereas 
the opposite occurs in peripubertal  ages62. GPER is present in Sertoli cells from the time of pubertal  onset63. 
Clinical observations in humans and experimental models indicate that ERα is required for spermatogenesis 
and maintenance of sperm morphology and  motility64,65 while ERβ is required to induce the fate of testicular 
cells in the undifferentiated  gonad66. GPER mediates direct effects of oestrogens on germ cells in  mice67. Finally, 
all ERs seem to be involved in proliferation and maturation of Sertoli cells in rodents and  boar62,63,68. Little is 
known about the direct effects of oestrogens in the prepubertal human  testis69. While no major clinically evident 
testicular dysfunction has been observed in males with genetic forms of aromatase  deficiency70, a patient with 
oestrogen insensitivity due to an ERα defect had high serum E2 and gonadotropin levels, but low AMH and 
inhibin B, suggesting a potential deficiency in Sertoli cell  function71.
In this work, we tested the hypothesis that E2 upregulates AMH expression in peripubertal Sertoli cells, 
thus explaining the increased levels of AMH observed in paediatric patients with hyperoestrogenic states, and 
explored the molecular mechanisms potentially involved.
Results
Presence of ERα and ERβ in testes of patients with androgen insensitivity. To address the physi-
ological and pathophysiological relevance of our hypothesis in humans, we first assessed the presence of ERα and 
ERβ in testicular tissue of 46,XY patients with CAIS, an hyperoestrogenic condition. Immunohistochemistry of 
testicular tissue obtained from archival samples of gonadectomy from four patients with CAIS showed the pres-
ence of ERα and ERβ in Sertoli cells (Fig. 1). We compared this expression pattern with that observed in four 
biopsies of prepubertal human testes without injury, obtained from archival samples of paediatric patients with 
acute lymphoblastic leukaemia in which absence of gonadal involvement was verified. We detected the presence 
of ERα and ERβ in the Sertoli cells of normal testicular tissue and of patients with CAIS, which had scarce germ 
cells in the seminiferous tubules (Fig.  1). Although immunohistochemistry is not quantitative, ERα staining 
seemed somewhat more intense than that of ERβ in cell nuclei. These results indicate that Sertoli cells of patients 
with CAIS express oestrogen receptors, setting the basis for a potential AMH increase in response to elevated 
oestrogen levels.
Effect of anti-oestrogen treatment on serum AMH in prepubertal male mice. To test the effect 
of E2 on AMH production before pubertal testis maturation, we treated male CF-1 mice with E2 from post-
natal day 4 to day 8, and measured serum AMH and E2 levels on postnatal day 9. We observed no significant 
changes in serum AMH as compared to control mice, but we noted that the treatment protocol could not achieve 
increased E2 levels but rather reduced them (Fig. 2A), so it was uninformative. As an alternative strategy, we 
treated 4-day-old male mice with a single dose of the ERα- and ERβ-antagonist ICI 182780. At 9 days of age, 
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Figure 1.  Immunohistochemistry for ERα and ERβ. A-H: Normal prepubertal human testis (biopsy showing 
unaffected tissue from a 7-year-old boy with acute lymphoblastic leukaemia). I-P: Testis from a 6-year-old 
patient with complete androgen insensitivity syndrome (CAIS). HE haematoxylin–eosin, IgG primary antibody 
was replaced by IgG from nonimmune serum (negative control), IT interstitial tissue, ST seminiferous tubule; 
arrows: Sertoli cells (ovoid or elongated nuclei); arrowheads: germ cells (spermatogonia, round nuclei and 
abundant pale cytoplasm). Detection was performed using HC-20 antibody for human ERα, and Ab1531 for 
human ERβ. The bars represent 60 µm.
Figure 2.  Serum AMH and E2 levels in mice. (A) Serum levels of AMH and E2 in 9-day-old male mice treated 
sc with E2 (20 µg/day) or vehicle from postnatal day 4 to day 8. (B) Serum levels of AMH and E2 in 9-day-old 
male mice treated sc with ICI 182780 0.8 mg (single dose) or vehicle on postnatal day 4. * P < 0.05, Student’s 
t-test for unpaired samples, n = 8.
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we observed a significant decrease in serum AMH as compared to control mice (Fig. 2B). These results suggest 
that blocking the ER pathway causes a decrease in testicular AMH output, in line with our hypothesis that E2 
stimulates the secretion of AMH.
AMH expression in response to various E2 doses in SMAT1 Sertoli cells expressing ERα or 
ERβ. The study of the molecular mechanisms underlying the potential effects of E2 on AMH expression were 
performed using the SMAT1 cell line, derived from a previously characterised immortalised cell line of mouse 
prepubertal Sertoli  cells23,25,33,72. Since it had not been previously studied, we first showed that SMAT1 cells 
express neither ERα nor ERβ (Fig. 3A). Accordingly, incubation with E2 induced no changes in the activity of a 
3,078-bp human AMH promoter (pGL2B-5′hAMH-3078) in luciferase assays (Fig. 3B).
By transfecting the expression plasmids pSG5-ERα or pSG5-ERβ, we achieved expression of both ERs 
(Fig. 3A). Next, we evaluated the responsiveness to E2 of SMAT1 cells transfected with pSG5-ERα or pSG5-ERβ, 
in terms of activation of pGL2B-5′hAMH-3078. Maximal activation of the AMH promoter was observed with E2 
 10–10 M in ERα-transfected and with E2  10–7 M in ERβ-transfected SMAT1 cells (Fig. 3C). In cells transfected with 
both ERs, the E2 response profile was similar to that observed in cells transfected with ERα alone. The subsequent 
experiments were performed using E2  10–9 M because that is the physiological intratesticular E2 concentration 
estimated in male adolescents and patients with  CAIS73. The activity of pGL2B-5′hAMH-3078 was significantly 
increased in SMAT1 cells transfected with ERα, but not with ERβ (Fig. 3D). Therefore, we performed the rest of 
the experiments using ERα-transfected SMAT1 Sertoli cells.
We validated the effect of E2 on AMH protein expression in SMAT1 Sertoli cells transfected with pSG5-ERα 
and incubated with E2  10–9 M (Fig. 3E). The intensity of AMH immunofluorescent staining in individual cells, 
measured with ImageJ software, was significantly increased in ERα-expressing cells relative to neighbouring 
cells that did not express ERα. These results confirm that E2  10–9 M, through ERα, increases endogenous AMH 
expression in SMAT1 Sertoli cells.
Effect of ERα agonists and antagonists on AMH promoter activity. We further verified that the 
effect of E2  10–9 M on the activity of the 3,078-bp hAMH promoter in SMAT1 Sertoli cells is mediated by ERα 
in luciferase activity assays after performing transient transfection experiments with pSG5-ERα and pGL2B-
5′hAMH-3078-luc. The ERα and ERβ antagonist ICI 182780 significantly reversed the E2-induced hAMH pro-
moter activity (Fig. 4A). PPT, a potent and selective ERα agonist, caused a significant stimulation of hAMH 
promoter activity while MPP, a silent and selective antagonist of ERα, induced a significant inhibition of the 
hAMH promoter activity (Fig. 4B). These results indicate that ERα mediates the increased hAMH promoter 
activity observed in SMAT1 Sertoli cells exposed to the E2 levels observed in human physiological/pathophysi-
ological conditions.
Human AMH promoter sequences responsive to E2. Next, we tested the involvement of the half-
ERE site present at − 1,782 bp of the hAMH promoter in response to E2 in ERα-expressing SMAT1 Sertoli cells. 
The increased activity of the 3,078-bp hAMH promoter observed in response to E2 was abolished in SMAT1 
cells transfected with a construct of the hAMH promoter carrying an inactivating ERE mutation (Fig. 5A). The 
response of the hAMH promoter to E2 was maintained, albeit at a somewhat lower level, when a 1926-bp pro-
moter with an intact ERE was used. Conversely, no response was seen when hAMH promoters carrying exclu-
sively the proximal 433 bp or sequences ranging from – 1,926 to − 3,078 bp or from – 1,926 to − 2,590 bp, i.e. 
lacking the ERE, were used.
The existence of a direct interaction between ERα and the half-ERE at – 1,782 of the hAMH promoter was 
tested in electro mobility shift assays (EMSA), performed with nuclear extracts from SMAT1 cells transfected 
with ERα and incubated with E2  10−9 M for 24 h prior to nuclear extraction (Fig. 5B). Complex formation 
Figure 3.  Luciferase assays to assess human AMH promoter (3,078 bp) activity in SMAT1 cells. (A) Western 
blot for ERα (left) and ERβ (right) in SMAT1 cells, non-transfected or transfected with pSG5-ERα or pSG5-ERβ, 
in MCF-7 cell line and uterus—that endogenously express ERα—and in KGN cell line endogenously expressing 
ERβ. Detection was performed using the following antibodies: HC-20 (human ERα), MC-20 (murine ERα), 
1531 (human ERβ) and Y-19 (murine ERβ). Representative of 3 experiments. (B) Cells transfected with pGL2B 
or pGL2B-5′hAMH-3078, but not transfected with ER expression vectors were exposed to E2  10–9 M or basal 
medium. % RLU: relative luciferase units, considering the baseline condition (pGL2B without E2) as 100%. 
Student’s t-test for paired data, n = 4. (C) Cells transfected with pGL2B-5′hAMH-3078, and co-transfected with 
pSG5-ERα, pSG5-ERβ or both, were exposed to E2 from 0 to  10–7 M. The grey curve repeated in all figures 
corresponds to SMAT1 cells not transfected with ER vectors. % RLU: relative luciferase units, considering 
the baseline condition (without ER and without E2) as 100%. * P < 0.05 ERα or ERβ or ERα + ERβ vs no ER, 
Student’s t-test for paired data, n = 4. (D) Cells transfected with pGL2B-5′hAMH-3078, and co-transfected with 
pSG5, pSG5-ERα, pSG5-ERβ or both, were exposed to E2  10–9 M or basal medium. % RLU: relative luciferase 
units, considering the baseline condition (without ER and without E2) as 100%. *** P < 0.001 ERα or ERβ or 
ERα + ERβ vs no ER, analysis of variance (ANOVA), followed by Tukey’s multiple comparison test, n = 8. (E) 
Endogenous expression of AMH protein in SMAT1 cells transfected with ERα and exposed to E2  10-9 M. The 
intensity of AMH immunofluorescence (green) was compared between SMAT1 cells effectively transfected 
with pSG5-ERα (red) and neighbouring non-transfected cells. Quantifications are shown on the right panel; * 
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observed with the ERE wild-type radioactive probes, but not the mutant ERE probes, was displaced with increas-
ing concentrations of excess cold probe (250 × to 500 ×), which supports the specificity of the binding.
Taken together, these results indicate that E2  10–9 M, through ERα, increases the activity of the hAMH 
promoter in SMAT1 Sertoli cells, using the half-ERE site present at – 1,782 bp of the hAMH promoter. We can-
not rule out that other sequences present upstream of – 1,926 are also involved in the activation of the hAMH 
promoter in response to E2.
Involvement of GPER in hAMH promoter responsiveness to E2 in SMAT1 Sertoli cells. GPER 
expression in Sertoli cells, described in  rats63, is not conserved in SMAT1 cells (Fig. 6A,B). Therefore, to test 
whether GPER may mediate E2 action on hAMH promoter activity, we transfected SMAT1 cells with pcDNA3-
GPR30-GFP56 expression vector for GPER (Fig. 6C) and incubated them with increasing concentrations of E2 
(Fig. 6D). Maximal activity of the 3,078-bp hAMH promoter was seen with E2  10–9 M, corresponding to physi-
ological oestrogen concentrations, as already mentioned.
The modest but significant effect of E2 on the activity of the 3,078-bp hAMH promoter mediated by GPER 
was also observed when E2 was replaced by G1, a potent and selective GPER  agonist63, but reversed when the 
selective GPER antagonist G-15 was added (Fig. 6E). These results indicate that, in addition to ERα, GPER may 
also be involved in E2-induced increase of the hAMH promoter activity.
Discussion
Testicular AMH production is increased in different clinical conditions characterised by elevated oestrogen levels. 
In this work, we show that E2 in the concentration range observed in those conditions is capable of inducing an 
upregulation of endogenous AMH protein expression as well as of the hAMH promoter activity in the prepubertal 
Sertoli cell line SMAT1. This process mainly involves ERα binding to a specific ERE sequence present at position 
– 1,782 of the hAMH promoter and also, more modestly, the membrane receptor GPER. At higher concentrations, 
the effect could also be attained via the ERβ receptor. The ERα and ERβ antagonist ICI 182780 downregulated 
hAMH promoter activity in SMAT1 cells and resulted in a decrease in serum AMH levels in prepubertal male 
mice. Finally, we confirmed that ERα expression is conserved in Sertoli cells in testicular tissue from patients 
with CAIS and both ERα and ERβ are expressed in Sertoli cells of normal prepubertal testicular tissue.
The main physiological role of AMH in mammals is the induction of Müllerian duct regression in the early 
stages of fetal life in males. Its persistent secretion by the testes after sex differentiation is completed and its 
production by the ovaries have led to the search for other biological functions for AMH. Regardless of the 
existence of other potential functions, AMH has become a useful clinical biomarker of testicular function in 
paediatric  ages74,75, when circulating levels of testosterone and gonadotrophins—the typical markers of the male 
reproductive axis in adults—are low and may be of little clinical  help76. The usefulness of AMH to interpret 
pathophysiological conditions has increased as the mechanisms underlying its production have been unveiled. 
The fact that basal AMH expression is independent of gonadotrophins explains that sex differentiation can occur 
before the fetal hypothalamic-pituitary–gonadal axis is functional, whereas its upregulation by FSH through 
Gsα protein signalling justifies the low AMH levels observed in newborns with congenital hypogonadotrophic 
 hypogonadism77,78 and high levels in boys with McCune-Albright  syndrome22. Downregulation of AMH expres-
sion by androgens, through AR interaction with the transactivating factor  SF129, underlies the decrease of serum 
AMH in both normal and precocious puberty in  males26, whereas the lack of AR expression in the fetal and early 
infantile Sertoli  cells31–33 explains why AMH remains high in spite of intratesticular androgen concentrations 
similar to those seen in adults and in boys with precocious puberty diagnosed before the age of 1 year34. In brief, 
the knowledge on the signalling pathways that regulate AMH testicular production have served to potentiate its 
Figure 4.  Effect of ER agonists and antagonists on hAMH promoter activity in SMAT1 cells. (A) Activity of 
pGL2B-5′hAMH-3078 in cells transfected with pSG5 or pSG5-ERα in basal conditions (considered as 100% of 
relative luciferase, RLU) and after incubation with E2  10–9 M and/or the selective antagonist ICI 182780  10–6 M. 
*** P < 0.001, analysis of variance (ANOVA), followed by Tukey’s multiple comparison test, n = 8. (B) Activity 
of pGL2B-5′hAMH-3078 in ERα-transfected cells in basal conditions (considered as 100% of RLU) and after 
incubation with E2  10–9 M, the selective ERα agonist  10–6 M PPT or the selective ERα antagonist MPP  10–8 M. * 
P < 0.05, t-test for one sample compared to theoretical value of 100% (basal), n = 3.
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use as a biomarker of gonadotrophin and steroid action in the prepubertal and pubertal  testis79. In this work, 
we shed light on the molecular mechanisms that underlie AMH regulation by E2, providing insight into the 
potential biological processes that are responsible for the coincident increase in oestrogens and AMH in patients 
with hyperoestrogenic states, like  CAIS36,37 and Peutz–Jeghers  syndrome43.
Several observations led us to test the hypothesis that oestrogens induce an increase in AMH and not the 
opposite. On one hand, sequences compatible with a binding site for the ER have been described on the hAMH 
 promoter45. On the other hand, in the ovaries AMH downregulates  aromatase80,81, the enzyme responsible for 
E2 synthesis from testosterone, and E2 increases AMH  expression46. Particularly in patients with CAIS who have 
not been gonadectomised before the age of puberty, FSH  increases82 and acts on Sertoli cells which remain at 
an immature state owing to the lack of androgen action in spite of high testosterone production. FSH is known 
to activate aromatase in Sertoli  cells48,83, which are then capable of metabolising testosterone to E2. In pubertal 
patients with CAIS, circulating E2 levels are between 20 and 250 pmol/l (i.e. in the  10–10 to  10–11 M range)82, and 
intratesticular concentrations are usually 400-fold higher (i.e. in the  10–8 to  10–9 M range)73. We exposed SMAT1 
Sertoli cells to E2 at  10–9 M in our experiments in order to mimic CAIS conditions, thus supporting the biological 
Figure 5.  Relevance of the ERE site for E2 regulation of the hAMH promoter. (A) Luciferase activity of 
various pGL2B-5´hAMH constructs in SMAT1 Sertoli cells co-transfected with pSG5-ERα and incubated in 
basal conditions (considered as 100% of the relative luciferase units, RLU) or with E2  10–9 M. The percentage 
value reflects the response (E2/basal × 100). ERE: half-oestrogen response element present at position −1,782 
of the human AMH promoter. * P < 0.05, *** P < 0.001, t-test for one sample compared to theoretical value 
of 100% (basal), n = 3. (B) Electro-mobility shift assay (EMSA) to test ERα binding to the hemi-ERE present 
at – 1,782 of hAMH promoter. Nuclear extracts from SMAT1 cells (between 0 and 10 µg) were incubated with 
a 32P-labeled DNA probe spanning the sequence of the wild-type (WT) or mutated (mut) hemi-ERE site and 
an excess (250 × or 500 ×) of ERE unlabelled WT probe. The arrow indicates the band corresponding to the 
WT ERE probe. Lane 1 does not contain nuclear extract. Lanes between 6 and 7, with irrelevant or duplicated 
experimental conditions, were cropped (for full-length blot, please see Supplementary material).
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plausibility of our hypothesis. According to our results, we privilege ERα and, to a lesser extent GPER, as the 
most likely mediators of oestrogen action on the AMH promoter activity, since ERβ only conveyed a significant 
response when SMAT1 cells were exposed to E2 at  10–7 M, i.e. a concentration tenfold higher than that expected 
within the testes. Our results indicate that there are differences between the Sertoli cell of the peripubertal testis 
and the granulosa cell of the adult ovary as regards to AMH regulation by E2. We show here that ERα seem to 
be the physiological mediator of E2 stimulatory effect on AMH expression whereas ERβ would be stimulatory 
only at supraphysiological levels. Conversely, in the adult ovary, ERα and ERβ show opposing effects, and the 
resulting AMH transcriptional activity depends on the ERα/ERβ expression ratio in granulosa  cells46.
To support the physiological and pathophysiological relevance of our findings we verified the expression 
of ERs in testicular tissue from patients with CAIS. We could confirm that ERα, which we prioritised for the 
oestrogenic effect on AMH promoter activity, is present in Sertoli cells. Expression of ERα and ERβ in testicu-
lar tissue is controversial in the literature (for review, please see  ref58). Our results are in keeping with those 
Figure 6.  Relevance of GPER signalling in E2 regulation of the hAMH promoter. (A–C) Characterisation of 
GPER expression in SMAT1 cells: (A) electrophoresis after RT-PCR for GPER. L: 100-bp ladder, C + : positive 
control from human kidney cells, I: non- transfected SMAT1, II-IV: SMAT1 transfected with pcDNA3-GPR30-
GFP (II: without RT enzyme, III: without cDNA): a ~ 540-bp band indicating GPER expression is observed in 
the transfected cells as well as in the positive control; (B) immunofluorescence in non-transfected SMAT1 cells; 
(C) immunofluorescence in SMAT1 transfected with pcDNA3-GPR30-GFP (arrows indicate positive cells, 
with higher magnification in the bottom figure). (D) SMAT1 cells transfected with pGL2B-5′hAMH-3078, and 
co-transfected with pcDNA3-GPR30-GFP were exposed to E2 from 0 to  10–8 M. The grey curve corresponds 
to SMAT1 cells not transfected with GPER. % RLU: relative luciferase units, considering the baseline condition 
(without GPER and without E2) as 100%. (E) Activity of pGL2B-5′hAMH-3078 in SMAT cells transfected or 
not with pcDNA3-GPR30-GFP in basal conditions (B, considered as 100% of relative luciferase, RLU) and 
after incubation with E2  10–9 M, the selective GPER agonist G-1 (100 nM) and the selective antagonist G-15 
(100 nM). * P < 0.05, analysis of variance (ANOVA), followed by Sidak’s multiple comparison test-all versus B 
(basal) for each set (non-transfected or GPER-transfected), n = 10.
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previously reported by Cavaco and  colleagues60 using the same antibody, but intensity seems somewhat lower 
in the nuclei. Like for other steroid receptors, nuclear localisation may be weaker in prepubertal ages, when 
steroid levels are very  low32. Other reports found no ERα staining in Sertoli and germ  cells59,84. These divergent 
observations might be explained by the existence of different ERα  isoforms85 and the capacity of the antibodies 
used to detect them by immunohistochemistry. GPER is also expressed in Sertoli cells, as previously shown in 
young  males61. Unfortunately, the proven antibody used for immunohistochemistry in the referenced work was 
no longer available at the moment of our study.
One strength of our study is the use of SMAT1 cells as a model of prepubertal Sertoli cells. The expression of 
AMH declines significantly during pubertal development, and most Sertoli cell lines derived from adult testes do 
not express  AMH72,86. SMAT1 cells maintain AMH expression, indicating that the basal transcriptional machin-
ery for AMH is  present72; indeed, its validity for the study of AMH regulation has been already  proven23–25,29,33,87. 
However, SMAT1 cells have lost the expression of all oestrogen receptors, as shown in the present work. While 
this may seem a limitation, requiring transfection of oestrogen receptor expression vectors in all experiments, it 
represented an advantage to test specificity of our results since we could use exposure of non-transfected SMAT1 
cells to E2, agonists and antagonists as a negative control. We verified the expression of oestrogen receptors in 
SMAT1 cells with various antibodies to ERα and ERβ. For GPER, we could not obtain reliable results with anti-
bodies, hence we confirmed its expression by RT-PCR. The specificity of the oestrogen receptors types involved 
was probed by using different agonists and antagonists. ICI 182780 is a high affinity ERα and ERβ antagonist, 
devoid of any partial agonism on  them88,89. PPT is a potent and selective ERα  agonist90, while MPP is a silent 
and selective ERα  antagonist89. Finally, G-1 is a potent and selective GPER agonist whereas G-15 is a selective 
antagonist, displaying no activity at ERα and ERβ55. The GPER-mediated effect was only moderate, up to 1.4-fold 
as seen in our dose-dependent experiments with E2 shown in Fig. 6D. This modest effect seems to be comparable 
with those previously shown for other markers of GPER-mediated oestrogen action in Sertoli cells, such as BCL2 
and  BAX63. Whether an additive effect in physiological conditions in Sertoli cells expression all three ERs exist 
could not be tested in our experimental conditions, requesting co-transfections of all receptors.
Using targeted mutagenesis to modify the ERE sequence present on the hAMH  promoter45 and also previ-
ously validated promoter constructs of different  sizes23–25,29, we could provide further insight into the molecular 
mechanisms that explain E2 regulation of AMH expression. In fact, only the hAMH promoter variants containing 
the ERE sequence at – 1,782 were responsive to E2 incubation in the presence of ERα. The short hAMH promoter 
of 433 bp and the constructs containing sequences ranging from – 1,926 to − 3,078 bp or – 1,926 to − 2,590 bp, 
i.e. lacking the ERE sequence at – 1,782 bp, as well as the 3,078-bp promoter carrying an inactivating mutation 
of the ERE sequence showed no response when SMAT1 cells were exposed to E2. These results were further 
supported by the EMSA experiments. Unfortunately, although we tested several experimental conditions, we 
could not show a displacement in EMSA when using anti-hERα antibodies, which could be explained by a poor 
antibody-protein complex ratio of human ERα in these experimental conditions.
To corroborate in vivo the effect of E2 on AMH production by Sertoli cells, we attempted various protocols 
of oestrogenisation in prepubertal male mice. Unfortunately, the attempts proved unsuccessful, as indicated 
by the serum levels of E2 found in the mice after sacrifice. The experimental design was based on the fact that 
testicular AMH production falls significantly after postnatal day 10 in male  mice19; therefore, any treatment with 
E2 should be given very early after birth. Another important issue is that sufficient levels of steroids need to be 
attained within the testes for a response to be observed. Indeed, because steroids are produced within the gonads, 
their intratesticular concentration usually reaches levels that are 100–1,000-fold higher than those observed in 
 circulation73, and the usual steroid doses used in treatments targeting peripheral tissues—like genitals, muscle 
and bone—are ineffective to induce changes in Sertoli cell AMH  production91. This means that the dose of E2 
needed to be injected was unusually high, and it proved impossible to attain in the small volume that could be 
injected to mice aged 4–8 days weighing less than 5 g. The maximal E2 dose we could use probably inhibited 
FSH in treated mice, which may explain a potential decrease in the endogenous E2 production by the gonads. 
Nonetheless, mice treated with the potent ERα- and ERβ-antagonist ICI  18278088,89, commercially known as 
fulvestrant  (Faslodex®), showed a significant decrease in serum AMH levels, thus supporting our hypothesis that 
oestrogens are involved in testicular AMH output. Alternative explanations are possible since ICI 182780 has an 
agonist effect on  GPER92, although it seems to be weaker than the antagonist effect on ERα and ERβ93. Although 
we focused on a direct transcriptional regulation of AMH by E2, other mechanisms may also be implicated, e.g. 
translocation of ERα to the cell membrane inducing the MAPK3/1 phosphorylation  cascade94 and/or a Sertoli 
cell mass effect. In fact, ERα and ERβ62,63,94, as well as  GPER68 have been shown to induce prepubertal Sertoli cell 
proliferation, which could result in higher serum AMH levels as observed in  mice23 and  humans22.
In summary, E2 upregulates AMH expression by increasing the activity of the hAMH promoter in the prepu-
bertal Sertoli cell line SMAT1. Signalling through ERα, which binds to a specific ERE sequence present 1,782 bp 
upstream of the hAMH translation start site, seems to be the most relevant underlying mechanism. A more 
modest effect may also be conveyed through the membrane receptor GPER (Fig. 7). Other potential mechanisms 
include translocation of ERs to the plasma membrane with activation of MAPK3/1 and/or boosting of Sertoli cell 
proliferation. The evidence presented here provides biological plausibility to the proposal that testicular AMH 
production increases in various clinical conditions in response to elevated oestrogen levels.
Methods
Human tissues for immunohistochemistry. Testicular tissue from patients with the diagnosis of Com-
plete Androgen Insensitivity Syndrome (CAIS) and from patients with acute lymphoblastic leukaemia was 
obtained from the archives of the Pathology Laboratory of CEDIE at Hospital de Niños Ricardo Gutiérrez. CAIS 
patients (n = 4) were 4 to 9 years-old, raised and females, and diagnosed due to either a familial history (sibling) 
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with CAIS or as an unexpected finding during a surgery for hernia. As control of prepubertal testicular tissue, 
we used the normal testicular tissue present in biopsies routinely obtained before chemotherapy to rule out tes-
ticular compromise in boys with acute lymphoblastic leukaemia (n = 4), aged 4 to 7 years old. The study protocol 
was approved by the Institutional Review Board (Comité de Docencia e Investigación) and Ethics Committee 
(Comité de Ética en Investigación, protocol number CEI-17.01) of the Hospital de Niños Ricardo Gutiérrez de 
Buenos Aires. The study was performed in accordance with relevant international guidelines, such as the World 
Medical Association’s Declaration of Helsinki on Medical Research Involving Human Subjects, and Declaration 
of Taipei on Ethical Considerations Regarding Health Databases and Biobanks, and local regulations, such as law 
3301/2009 of the Government of the City of Buenos Aires on Protection of Rights of Subjects in Health Research 
and its regulatory decree 58/2011, and the resolution 595/2014 of the Ministry of Health of the City of Buenos 
Aires on Requirements and Procedures Applicable to Behavioural, Socio-anthropological and Epidemiological 
Research Projects. Owing to its retrospective design with descriptive purposes and no anticipated effect on the 
prognosis or therapeutic management of the patients whose tissue samples were included, the need for a written 
informed consent was waived.
Animals. Outbred CF-1 female pregnant mice (Mus musculus), obtained from Facultad de Ciencias Exactas 
y Naturales, Universidad de Buenos Aires, were kept in the animal facility of the Hospital de Niños Ricardo 
Gutiérrez on a 12:12 light–dark cycle, with food pellets and water ad libitum in cages, with their pups when born. 
Male offspring, used in the experiments, were sacrificed by cervical dislocation at postnatal day 9. Research 
using animals was performed in compliance with the Guide for the Care and Use of Laboratory Animals, 8th ed. 
Washington, DC: National Research Council, National Academies Press, 2011.
Hormone assays. Serum was extracted and stored at − 20 °C until assayed. AMH was measured by 
enzyme-linked immunoassay using AMH Gen II  ELISA® (Beckman-Coulter Inc.), with a functional sensitivity 
Figure 7.  Proposed model for oestradiol (E2) regulation of the testicular AMH production in Sertoli cells. 
E2 upregulates AMH transcription mainly through nuclear oestrogen receptor α (ERα) binding to a specific 
oestrogen response element (ERE) on the AMH promoter, located 1,782 bp upstream of the translational start 
site. More modestly, GPER activation also upregulates AMH expression. The increased AMH expression results 
in a higher testicular AMH production. Another potential mechanism, not studied in this work, which could 
increase testicular AMH production is the increase in Sertoli cell proliferation induced by membrane-bound 
ERα, signalling through the PI3K/Akt pathway, and/or GPER, through MAPK signalling (dotted lines).
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of 2.5 pmol/l and intra- and inter-assay coefficients of variation of 9.4% and 10.5%, respectively. E2 was deter-
mined with an electrochemiluminescent assay (ECLIA, Roche Diagnostics GmbH), with a functional sensitivity 
of 10 pg/ml, an intra-assay coefficient of variation of 3.8% and an inter-assay coefficient of variation of 6.5%.
plasmids. The plasmids used in luciferase assays are shown in Supplementary Table S1.
Site-directed mutagenesis. The plasmid of the hAMH promoter with the mutated ERE half-site was 
generated using the QuikChange II XL Targeted Mutagenesis Kit (Stratagene), as  described15. Oligonucleotide 
primers for mutagenesis (Supplementary Table S2) were synthesised by Eurogentec (Liège, Belgium). Sequence 
changes were verified by direct sequencing, performed at Eurofins MWG (Ebersberg, Germany).
cell lines. SMAT1 cell line is a clonal line of immortalised Sertoli cells, obtained from pre-tumour testes 
of 6.5-day-old transgenic mouse expressing the SV40 oncogene under control of the AMH  promoter72. This 
cell line has characteristics that make it extremely useful to study the physiology of the prepubertal Sertoli cell, 
maintaining the expression of both AMH and SOX9, GATA4 and  SF123,25. MCF-7 is a human breast cancer cell 
line that expresses high ERα  levels95. KGN cell line was established from a human ovarian granulosa cell tumour 
highly expressing ERβ96. Human renal tubular epithelial cells (HRTEC) express  GPER97.
Reverse-transcriptase (Rt) and polymerase chain reaction (pcR). Expression of GPER was stud-
ied in SMAT1 cells by RT-PCR. Cells were grown in culture medium (as described above) in six-multi-well 
plates and RNA was obtained using TRI  Reagent® (Sigma T9424) following manufacturer’s instructions. Briefly, 
TRI  Reagent® was added to each well (1 ml per well) and incubated 5 min at room temperature. After collecting 
cell lysates, 200 μl of chloroform were added and incubated 2 min at room temperature. After centrifugation for 
15 min at 15,000 × g at 4 °C, the aqueous phase was retrieved in clean tubes and 500 μl of isopropanol were added 
and incubated 10 min at room temperature and subsequently stored overnight at − 20 °C to increase RNA yield. 
After thawing at room temperature, samples were centrifuged for 60 min at 15,000 × g at 4 °C. Supernatants 
were discarded and pellets washed twice with ethanol 75% and once with ethanol 100%, followed by a 60 min 
centrifugation at 12,000 g at 4 °C. Ethanol was removed and pellets allowed to air-dry. The RNA pellets were 
resuspended with RNAse free water (20 μl final volume). Genomic DNA remnants were eliminated by treatment 
with RQ1 RNase-free DNase (Promega M6101). Concentration and quality of RNA was assessed by spectro-
photometry. cDNA was obtained by reverse transcription using the MMLV I enzyme (Invitrogen) following 
manufacturer’s instructions. Briefly, 2 μg of RNA were used per reaction. Random hexamer primers (100 mM) 
and dNTPs (10 mM each, Invitrogen) together with the diluted RNA were incubated for 5 min at 65 °C and then 
placed on ice for at least 1 min. Subsequently, 7 μl of First Strand Buffer 5 × and DTT 0.1 M mix were added 
and incubated for 2 min at 37 °C. Finally, 1 μl of MMLVI (200 U) was added and incubated for 10 min at 25 °C 
followed by 50 min at 37 °C and 15 min at 70 °C. cDNA was stored at − 20 °C until use. RT-PCR was performed 
using an Eppendorf thermocycler.
Specific primers were designed for the detection of transcripts of the mouse Gper1 and the human GPER1 
genes, using bioinformatics tools according to NCBI Blast https ://blast .ncbi.nlm.nih.gov and Primer3plus pro-
gram https ://prime r3plu s.com. Primers were synthesised by Eurofins MWG|Operon (distributor in Argentina: 
Tecnolab). Primer sequences used are shown in Supplementary Table S3. A standard PCR was performed for 
amplification of the mouse and human cDNA, using 2 µg of cDNA per reaction and the GoTaq enzyme (Pro-
mega), following the manufacturer’s instructions. Briefly, 5 µl of 5 × GoTaq Buffer with  Mg+2, 0.5 µl of dNTPs 
(10 mM each), 1 µl of each primer (1 µM), 0.125 µl of GoTaq (5U/µl) and 3 µl of sample, in a final volume of 25 μl. 
A negative PCR control was included in which no sample was added and the volume was replaced by water. The 
cycling program consisted of an initial cycle of denaturation for 10 min at 94 °C, followed by 30 cycles of 30 s 
of denaturation at 94 °C, 30 s of alignment at 60 °C and 1 min of extension at 72 °C, followed by a final cycle of 
extension of 10 min at 72 °C.
cell culture and luciferase assays. SMAT1 cells were cultured at 37  °C in a humidified atmosphere 
with 5%  CO2 in Dulbecco Modified Eagle Medium (Gibco 11995-065, Invitrogen) supplemented with MEM 
amino acids solution (Gibco 11130051), 10% fetal bovine serum (FBS, Gibco 16000-044), penicillin–strepto-
mycin (final concentration 50 U/ml, Gibco 15070-063) and amphotericin B (final concentration 0.0025 mg/ml, 
Sigma A-4888).
For luciferase assays, SMAT1 cells were transiently transfected with 0.5 µg/well of luciferase reporter plasmids 
containing hAMH promoter length variants or mutants and 0.2 µg/well of ERα, ERβ or GPER expression plas-
mids, using Lipofectamine 3000 (Invitrogen) as suggested by the manufacturer. The plasmid pRL-TK (0.15 µg/
well) was used as transfection control. Backbone plasmids were transfected to balance DNA amounts. Briefly, 
on day 1 SMAT1 cells were plated at 2 × 105 cells/well in 24 multi-well plates. On day 2, medium was changed to 
medium without penicillin–streptomycin and amphotericin B for 2 h, and subsequently to 1% charcoal-stripped 
FBS-DMEM without phenol red, 1% MEM. The DNA-Lipofectamine solutions were added in a 1:2 DNA-
Lipofectamine-Optimem (Gibco, 11058021) solution:transfection medium and incubated for 4 h. Transfection 
medium was then replaced by 10% charcoal-stripped FBS in DMEM, with amino acids, penicillin–streptomycin 
and amphotericin B, and incubated overnight. Cells were incubated with vehicle (ethanol), 17β-oestradiol (E2, 
Sigma E8875) or the following agonists or antagonists overnight in serum-free medium: (a) ICI 182780, a high 
affinity ERα and ERβ antagonist (IC50 = 0.29 nM), devoid of any partial agonism both in vitro and in vivo88,89, 
(b) PPT (4,4′,4′′-(4-Propyl-[1H]-pyrazol-1,3,5-triyl) trisphenol), a potent and selective ERα agonist with an 
effect 400-fold greater than on ERβ90, (c) MPP (1,3-bis (4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy) 
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phenol]-1H-pyrazoledihydrochloride), a silent, high-affinity selective ERα antagonist, with a 200-fold more pow-
erful effect than on ERβ89, (d) G-1 (1-[(3aR*,4S*,9bS*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-
3H-cyclopenta[c]quinolin-8-yl]-ethenone), a potent and selective GPER agonist, displaying no activity on ERα 
and ERβ at 10 µM (Tocris Bioscience)55, (e) G-15 [(3aS*,4R*,9bR*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-
3H-cyclopenta[c]quinoline], a potent and selective GPER antagonist, displaying no activity on ERα and ERβ at 
10 µM (Tocris Bioscience)55.
Luciferase activity was measured following the recommendations of the supplier of the dual luciferase kit 
(Promega E1910), and renilla luciferase (pRL-TK) was used as a transfection control, as  described25. After the 
culture medium was discarded and the cells were washed with PBS, 100 µl of PLB lysis buffer were added and 
incubated for 45 min at room temperature with shaking (120–150 rpm). Extracts were recovered, centrifuged 
at 14,000 rpm for 5 min at 4 °C. For luciferase activity assays, 45 µl of LAR II were added to 20 µl of supernatant 
from each sample and luminescence was measured on a Junior LB9509 luminometer (Berthold Technologies) 
or Synergy HTX multimode plate reader, coupled to software Gen5 (version 3.02, BioTek Instruments Inc.). 
For the measurement of renilla luciferase activity, 45 µl of Stop & Glo solution were added, and luminescence 
was measured. Results were expressed in relative luciferase units (RLUs), defined as the normalisation of firefly 
luciferase activity relative to renilla luciferase activity.
electro-mobility shift assays (eMSA). EMSA was performed as previously  described15. Briefly,  107 
SMAT1 cells plated in 75-cm2 flasks were transfected with 1 µg of pSG5-hERα and incubated with  10−9 M E2 
for 24 h prior to nuclear extraction. For the preparation of the nuclear extracts, cells were rinsed twice with ice-
cold PBS, resuspended in PBS and centrifuged at 1,000 × g for 5 min. The pellet was resuspended in buffer A 
containing protease inhibitors (10 mM HEPES pH 7.9, 1.5 mM  MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.1% 
Nonidet P-40, Phenylmethylsulfonyl fluoride 1 mM, 2 mg/l leupeptin, 2 mg/l aprotinin). After centrifugation, 
the crude nuclear pellet was resuspended in buffer C (10 mM HEPES pH 7.9, 0.2 mM NaCl, 0.2 mM EDTA, 25% 
glycerol) and incubated for 20–30 min with shaking at 4° C. After separating the cell components by centrifu-
gation at 12,000 × g for 5 min, the nuclear extracts were either directly evaluated or stored at – 80 °C. Protein 
concentration was determined with the Bradford Protein Quantification Assay (Bio-Rad).
For binding studies to the half-ERE site present at position – 1,782 of the hAMH promoter, double-stranded 
oligonucleotides (Supplementary Table S4) were end-labelled with γ-32P-ATP using T4 polynucleotide kinase 
(Promega). Unincorporated ATP was removed by column purification (Qiagen). Nuclear proteins (10 μg) were 
incubated with binding buffer (4% glycerol, 10 mM HEPES, pH 7.5, 1 mM dithiothreitol, 1 mM EDTA, 1 μg 
of poly dI-dC), 1 μg/μl BSA and the radiolabelled probe for 20 min at room temperature. Competition studies 
were performed in the presence of a molar excess of unlabelled probes. DNA–protein complexes were resolved 
by electrophoresis on a 5% non-denaturing polyacrylamide gel using Tris–borate-EDTA buffer. The gels were 
dried and subjected to autoradiography.
Immunohistochemistry and fluorescence microscopy. For immunohistochemistry, 5–7-µm sec-
tions of testis tissues from gonadectomy were used. The samples were deparaffinised in xylene for 30 min and 
rehydrated by successive passages in ethanol of decreasing concentration (100%, 96% and 70% in distilled 
water). The activity of endogenous peroxidase was inhibited with 10% hydrogen peroxide in ethanol/70% dis-
tilled water for 20 min. After a series of washes with PBS and blocking with 10% fetal bovine serum in PBS for 
1 h at room temperature in a humid chamber, sections were incubated with the primary antibodies overnight 
at 4  °C in a humid chamber. Primary antibodies are described in Supplementary Table  S5. Incubation with 
a biotinylated secondary antibody  (MultiLink® HK268 1:50 concentrated biotinylated anti-immunoglobulins) 
diluted 1:50 in blocking solution (10 fetal bovine serum % in PBS) was performed for 1 h at room temperature in 
a humid chamber. Finally, after a series of PBS washes, the reaction was developed using Avidin Biotin Complex 
(ABC kit Vectastain, Vector) and 3–3′-diaminobenzidine (DAB, DAKO). The analyses were performed using a 
Nikon Eclipse E800 light microscope, and photos were taken with a Nikon digital machine associated with this 
microscope using the ACT-2U software.
The expression of endogenous AMH and the ERα in SMAT1 cells was evaluated by immunofluorescence. 
After incubation in the dark in a humid chamber for 1 h at room temperature with the corresponding secondary 
antibody (mouse or rabbit anti-immunoglobulin) coupled to Alexa  Fluor® 488 or Alexa-Fluor® 594 (Abcam)98. 
Finally, the glasses were mounted with Vectashield (Vector) and sealed with enamel for observation with a Nikon 
Eclipse E800 microscope and image analysis with ImageJ  software99.
The expression of GPER in SMAT1 cells transfected with the GPER expression vector pcDNA3-GPR30-GFP56 
was verified by fluorescence microscopy in a Carl-Zeiss AxioScope A1 with filters for Hoechst 33342 (blue) and 
FITC (green). The images were obtained with the Axiocam ERc 5s camera and AxioVision LE software. Nuclei 
were counterstained with Hoechst 33342 (Invitrogen H1399).
Western blots. Western blots were performed as previously  described100. Briefly, SMAT1, MCF-7 or KGN 
cells or adult mouse uterine tissue were homogenised in TEGDS buffer with a polytron, after adding protease 
inhibitors. The homogenates were centrifuged for 10 min at 3,300 rpm at 4 °C, and the nuclei on the pellet were 
washed in TEDGS buffer plus 0.01% NP-40. The nuclei were resuspended in TEDGS containing 0.4 mol/l KCl 
and incubated at 4 °C for 30 min, and the nuclear homogenate was centrifuged at 12,000 rpm for 20 min at 4 °C. 
The nuclear extract was diluted 1:2 in TEDGS buffer with 30% glycerol, and proteins were quantified using the 
Lowry method. An amount of 100 μg total protein/lane was submitted to electrophoresis on 10% sodium dode-
cyl sulphate polyacrylamide gels (SDS-PAGE) using Laemmli’s buffer system. After electrophoresis, blotting was 
performed onto a nitrocellulose membrane and blocked overnight in 5% dry skimmed milk dissolved in 0.1% 
13
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15062  | https://doi.org/10.1038/s41598-020-71675-7
www.nature.com/scientificreports/
PBS -Tween 20. After several washes, the membranes were incubated with the primary antibodies described in 
Supplementary Table S5 at room temperature for 2 h. Blots were probed with sheep anti-mouse or donkey anti-
rabbit immunoglobulin, horseradish peroxidase-conjugated whole antibody (Abcam). The luminescent signal 
was generated with the ECL Western blotting detection reagent kit (GE Healthcare), and the blots were exposed 
to medical X-ray film for 10 s to 5 min.
Statistical analyses. Relative Luciferase Units (RLU) were defined as the normalisation of firefly luciferase 
against renilla luciferase activity. Values are expressed as mean ± SEM for the percentage (%) RLU as compared 
to samples exposed to vehicle (basal condition). Student’s t-test for unpaired samples, t-test for one sample 
compared to theoretical value of 100% (basal condition), or analysis of variance (ANOVA) followed by Tukey’s 
multiple comparison test or Sidak’s multiple comparison test were used as indicated in each figure legend. A 
difference was considered statistically significant when the P-value was < 0.05. All calculations were made using 
GraphPad Prism version 8 for Windows (GraphPad Software).
Sample size calculation was performed for the main outcome measures, as follow, based on pilot experiments. 
To show an increase of 50% in response to E2 through ERα or ERβ in transfected SMAT1 cells using a unilateral 
test, with a confidence level of 95% (α error < 0.05) and a statistical power of 80% (β error < 0.20), and an estimated 
variance of 900% for the unstimulated condition (control), a sample size of 4 was needed. For GPER, to show an 
increase of 15% in response to E2 using a unilateral test, with a confidence level of 95% and a statistical power of 
80%, and an estimated variance of 144% for the unstimulated condition (control), a sample size of 8 was needed.
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